Letzte Aktualisierung: 06.05.2026
Akute myeloblastische Leukämie [AML] [C92.0]
AMLSG 34-23 / HOVON 173
Studieninformationen
Ivosidenib and Azacitidine With or Without enetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Ziele
Primäres Prüfziel
EFS in patients with newly diagnosed IDH1-mutated AML, measured from the date of randomization to the date of treatment failure, hematologic relapse from CR/CRh or death from any cause, whichever occurs first; treatment failure is defined as not achieving either CR or CRh by week 24.
Sekundäre Prüfziele für die Behandlungsarme:
-
OS in patients with newly diagnosed IDH1-mutated AML, measured from the date of randomization to the date of death from any cause.
-
Rate of CR/CRh in patients with newly diagnosed IDH1-mutated AML, defined as the proportion of AML patients with CR/CRh at any time point during on-treatment period.
Design
Design
Phase
Zentren
Datenerhebung
Interventionsgruppen
Verblindung
Erkrankung
Diagnose
Diagnosenbeschreibung
Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML
Mutation
Patienten
Alter
Einschlusskriterien
Patient with newly diagnosed IDH1-mutated AML, or IDH1-mutated MDS/AML
Patient is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:
•
≥ 75 years of age ineligible for intensive chemotherapy per physician’s discretion (with an ECOG performance status 0-2; Appendix C).
•
18-74 years: patient is not eligible for standard chemotherapy because of any of the following co-morbidities:
o
ECOG performance status 2 or 3 (Appendix C).
o
Cardiac history of chronic heart failure requiring treatment; or with an ejection fraction ≤50%; or chronic stable angina.
o
Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% or FEV1 ≤ 65%.
o
Creatinine clearance ≥ 30 mL/min to <45 ml/min calculated by the Cockcroft Gault formula.o
Moderate hepatic impairment with total bilirubin > 1.5 to ≤ 3.0 x upper limit of normal (ULN).
o
Any other comorbidity that the local physician assesses to be incompatible with intensive chemotherapy. If a patient meets this criterion, sponsor must be informed via HO173@erasmusmc.nl.
Ausschlusskriterien
1.
Patient has previously been treated for AML; a treatment period with hydroxyurea to control WBC counts is allowed; prior treatment with a hypomethylating agent for MDS-EB is not allowed; prior treatment with erythropoiesis-stimulating agents or luspatercept for MDS is allowed.
2.
Acute promyelocytic leukemia (APL) with t(15;17)(q24.1;q21.2); PML-RARA; or one of the other pathognomonic variant chromosomal translocations / fusion genes.
3.
AML with BCR-ABL1; or myeloid blast crisis of CML.
Therapie
Intervention
Substanz
| Prüfplancode | AMLSG 34-23 / HOVON 173 |
|---|---|
| EudraCT | - |
| Clinicaltrials.gov | - |
|---|---|
| ISRCTN | - |
| DRKS | - |
Zuständige Gesamtstudie
—
Leiter der klinischen Prüfung (LKP)—
Studiengruppen/-zentrale
Kontakt Klinische Studien
CIO Aachen: Uniklinik RWTH Aachen, +49 (0) 241 80-85490
CIO Bonn: Uniklinik Bonn, +49 (0) 228 287-16036
CIO Köln: Uniklinik Köln, +49 (0) 221 478-0
CIO Düsseldorf: Uniklinik Düsseldorf, +49 (0) 211 81-04150 (Mo-Do)




